Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

The Lead

Amgen Laying Off at Least 2,400

July 30, 2014 10:20 am | by Linda A. Johnson, AP Business Writer | News | Comments

Biologic drugmaker Amgen said Tuesday that it will lay off 12 to 15% of its worldwide workforce and close four sites, even as it reported stellar second-quarter results trouncing Wall Street expectations and raised forecasts for its 2014 profit and revenue, driving up shares. Read more...

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Profectus BioSciences Snags $3.5M from NIH for HIV Vaccines

July 30, 2014 2:41 pm | News | Comments

Profectus BioSciences announced the award of two SBIR grants totaling $3.5 million from the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). Read more...        

TOPICS:

Treatment Combo Benefits Lung Cancer Patients

July 30, 2014 2:04 pm | News | Comments

A combination of the EGFR-targeted anticancer therapeutics Gilotrif and Erbitux yielded clinical responses in 29% of patients who had lung cancer harboring epidermal growth factor receptor mutations that had stopped responding to other inhibitors, according to new data. Read more...

TOPICS:

New Route to ID Bacterial Infection Drugs

July 30, 2014 1:41 pm | News | Comments

About 100 drugs already approved by the FDA for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires’ disease, brucellosis, and Mediterranean spotted fever. Read more... 

TOPICS:
Advertisement

Sage Licenses Gene Editing Tool from the Broad Institute

July 30, 2014 11:06 am | News | Comments

Sage Labs Inc., a leading provider of products, services and technologies in the field of genome engineering, announced that they have licensed CRISPR/Cas9 technology from the Broad Institute enabling them to use the CRISPR/Cas9 system to engineer cell and animal models for their clients as well as distribute validated CRISPR reagents. Read more...

TOPICS:

Diabetes Drugs Get Positive CHMP Opinions for CV Safety Updates

July 30, 2014 10:58 am | News | Comments

Takeda Pharmaceuticals International GmbH announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued positive opinions for updates to the Summary of Product Characteristics for Vipidia and the fixed-dose combination therapies Vipdomet and Incresync. Read more...

TOPICS:

AstraZeneca, Kyowa Hakko Kirin Partner on Immuno-Oncology Study

July 30, 2014 10:48 am | News | Comments

AstraZeneca announced that it has entered into a clinical study collaboration with Kyowa Hakko Kirin for a Phase 1/1b immuno-oncology study that will evaluate the safety and efficacy of two separate combinations of three investigational compounds in multiple solid tumors. Read more...

TOPICS:

European Commission Approves Eliquis for DVT, PE

July 30, 2014 10:37 am | News | Comments

Bristol-Myers Squibb Co. and Pfizer Inc. announced that the European Commission has approved Eliquis (apixaban) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE in adults. Read more...

TOPICS:

Researchers to Study BRCA1-Related Breast Cancer

July 30, 2014 10:26 am | by Ashley WennersHerron, Virginia Tech | News | Comments

Deborah Kelly and Zhi Sheng, assistant professors at the Virginia Tech Carilion Research Institute, recently received a grant from the Commonwealth Health Research Board to investigate hereditary breast cancer, an effort that may lead to new treatment approaches. Read more...

TOPICS:
Advertisement

Cancer Challenge Attracts Anonymous $100M Gift

July 29, 2014 2:54 pm | News | Comments

Oregon Health & Science University’s Knight Cancer Institute has received a $100 million gift to fuel its ambitious vision to stop cancer in its tracks. Read more...                       

TOPICS:

Neurotrope Initiates Phase 2a Alzheimer's Treatment Study

July 29, 2014 2:48 pm | News | Comments

Neurotrope Inc. announced that it has initiated a Phase 2a clinical trial to evaluate bryostatin for the treatment of patients with Alzheimer's disease (AD). Read more...                       

TOPICS:

FDA Approves Expanded Use of Imbruvica

July 29, 2014 2:43 pm | News | Comments

The FDA has approved the supplemental New Drug Application (sNDA) for Imbruvica (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. Read more...        

TOPICS:

Forced Mutations Doom HIV

July 29, 2014 2:32 pm | News | Comments

Fifteen years ago, researchers thought if they could induce the HIV virus to mutate uncontrollably, they could force it to weaken and eventually die out. But in a 2011 clinical trial, a drug based on this method did not eliminate the virus from patients. Now, researchers are aiming to develop better versions of that drug. Read more...

TOPICS:

$1,000 Sovaldi Now Choice Hep C Treatment

July 29, 2014 12:28 pm | by Ricardo Alonso-Zaldivar | News | Comments

The price may be high but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million. Read more...             

TOPICS:

Glaucoma Drug Gets EU Approval

July 29, 2014 11:18 am | News | Comments

Alcon, the global leader in eye care and a division of Novartis, announced that Simbrinza eye drops suspension has been approved by the European Commission to decrease elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, for which monotherapy provides insufficient IOP reduction. Read more...

TOPICS:

Artes, Burnet Institute Partner on Malaria Vaccine

July 29, 2014 11:13 am | by Catherine Somerville | News | Comments

Artes Biotechnology and Burnet Institute have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI), which will produce purified vaccine antigens as virus-like particles, a type of nano-particle, for testing in laboratory studies. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading